Abstracts tagged "spondyloarthritis"

Abstract Number: 1794 • ACR Convergence 2023
The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis
Archita Srinath¹, Daniele Mauro², Francesco Ciccia³ and Nigil Haroon⁴, ¹University of Toronto, Toronto, ON, Canada, ²University of Campania, Naples, Italy, ³University of Campania - Luigi Vanvitelli, Naples, Italy, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada
Background/Purpose: Inflammation and new bone formation are important disease mediators in ankylosing spondylitis (AS). Recent studies in mice show that the deubiquitinase molecule TRABID epigenetically…
Abstract Number: 2198 • ACR Convergence 2023
Which Factors Are Associated with Clinically High Disease Activity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Fernando Sommerfleck³, Christine Bundy⁴, Souzi Makri⁵, Jose Correa Fernandez⁶, Shashank Murlidhar Akerkar⁷, Jo Davies⁸, Elie Karam⁹, Asif Siddiqui¹⁰ and Denis Poddubnyy¹¹, ¹University of Seville, Sevilla, Spain, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Sanatorio Julio Mendez, Buenos Aires, Argentina, ⁴Cardiff University, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, ⁶Universidad de Sevilla, Health & Territory Research (HTR), Sevilla, Spain, ⁷Mumbai Arthritis Clinic, Mumbai, India, ⁸Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁹Canadian Spondylitis Association (CSA), Toronto, ON, Canada, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Active axial spondyloarthritis (axSpA) is associated with poorer physical and mental health outcomes. This study aims to assess the prevalence of clinically active disease…
Abstract Number: 2216 • ACR Convergence 2023
Hierarchy of Determinants of Work Impairment in Spondyloarthritis: Data from the Assessment of Spondyloarthritis International Society Health Index (ASAS-HI) International Validation Study
Frederico Rajão Martins¹, Pedro Carvalho², Désirée van der Heijde³, Manouk de Hooge⁴, Annelies Boonen⁵, Juergen Braun⁶, Uta Kiltz⁷ and Pedro Machado⁸, ¹Department of Rheumatology, University Hospital Centre of Algarve, Faro, Portugal, ²Hospital Particular do Algarve, Gambelas, Faro. Centro Académico de Lisboa, Lisboa, Portugal, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Ghent University Hospital, Hesperange, Luxembourg, ⁵Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁶Ruhr-Universität Bochum and Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany, ⁸Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom
Background/Purpose: Spondyloarthritis (SpA) is a disease of the working-age individual, with diverse economic and societal implications, including decreased employment rates. Our aim was to investigate…
Abstract Number: 2550 • ACR Convergence 2023
The Incidence of Uveitis in Patients with Axial Spondylarthritis Treated with Biologics or Targeted Synthetics: A Systematic Review and Network Meta-analysis
Zijing Yang¹, Maryam Adas¹, Bechman Katie¹, Deepak Nagra¹, Ali Soykan Uguzlar¹, Mark Russell¹, Nicky Wilson², Sophia Steer¹, Sam Norton¹ and James Galloway¹, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom
Background/Purpose: Anterior uveitis (AU) is one of the commonly observed extraspinal manifestations in Axial spondyloarthritis (AxSpA). Data on the protective effects of targeted immunomodulatory therapies…
Abstract Number: 0161 • ACR Convergence 2023
Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Brigitte Michelsen¹, Mikkel Østergaard², Michael Nissen³, Adrian Ciurea⁴, Burkhard Moeller⁵, Lykke Ørnbjerg⁶, Jakub Zavada⁷, Bente Glintborg⁸, Alan MacDonald⁹, Karin Laas¹⁰, Dan Nordstrom¹¹, Bjorn Gudbjornsson¹², Florenzo Iannone¹³, Pasoon Hellamand¹⁴, Tore Kvien¹⁵, Ana Maria Rodrigues¹⁶, Catalin Codreanu¹⁷, Ziga Rotar¹⁸, Isabel Castrejon¹⁹, Johan Karlsson Wallman²⁰, Jiri Vencovsky²¹, Anne Gitte Loft²², Maureen Heddle²³, Sigrid Vorobjov²⁴, Anna-Mari Hokkanen²⁵, Gerdur Maria Grondal²⁶, Marco Sebastiani²⁷, Marleen van de Sande²⁸, Eirik Kristianslund²⁹, Maria Jose Santos³⁰, Corina Mogosan³¹, Matija Tomsic³², Jose Federico Diaz-Gonzalez³³, Daniela Di Giuseppe³⁴ and Merete Hetland⁶, ¹Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ³Geneva University Hospitals, Geneva, Switzerland, ⁴University Hospital Zurich, Zürich, Switzerland, ⁵Inselspital - University Hospital Bern, Bern, Switzerland, ⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁹NHS Grampian, Aberdeen, United Kingdom, ¹⁰Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ¹³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁴Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ¹⁷Center for Rheumatic Diseases, Bucharest, Romania, ¹⁸University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²⁰Lund University and Skåne University Hospital, Lund, Sweden, ²¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²²Aarhus University, Horsens, Denmark, ²³Aberdeen Centre for Arthritis and Musculoskeletal Health, University of Aberdeen, Aberdeen, United Kingdom, ²⁴National Institute for Health Development, Tallinn, Estonia, ²⁵Helsinki University and Helsinki University Hospital, Helsinki, Finland, ²⁶Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²⁷Azienda Policlinico di Modena, Modena, Italy, ²⁸Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²⁹Diakonhjemmet Hospital, Oslo, Norway, ³⁰Hospital Garcia de Orta, Almada, Lisboa, Portugal, ³¹University of Medicine and Pharmacy, Bucharest, Romania, ³²University Medical Centre Ljubljana; Universitiy of Ljubljana, Ljubliana, Slovenia, ³³Hospital Universitario de Canarias, La Laguna, Spain, ³⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…
Abstract Number: 0514 • ACR Convergence 2023
Difficult-to-treat Axial Spondyloarthritis Is Associated with Psoriasis and Comorbidities: Results from a Nationwide Study
Olivier FAKIH¹, Maxime Desmarets², Bérenger Martin², Clément Prati¹, Elisabeth Monnet², Daniel Wendling³ and frank Verhoeven¹, ¹Service de rhumatologie, CHU de Besançon, Besançon, France, ²INSERM CIC-1431, Besançon, France, ³Besançon University Hospital, Besançon, France
Background/Purpose: An increasing number of targeted therapies are available for the treatment of SpA. However, some patients retain active disease despite several lines of treatment.…
Abstract Number: 0542 • ACR Convergence 2023
Two-Year Treatment Adherence and Clinical Response to Secukinumab Compared to TNF Inhibitors in Axial and Peripheral Spondyloarthritis Patients: A Single-Center Prospective Observational Study
Irini Flouri¹, Argyro Repa², Nestor Avgoustidis², Sofia Pitsigavdaki³, Katerina Pateromichelaki², Maria Terizaki², George Bertsias⁴ and Prodromos Sidiropoulos⁴, ¹University of Crete Medical School, Heraklion, Greece, ²Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Heraklion, Greece, ³Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Crete, Greece, ⁴Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece
Background/Purpose: Anti-IL17 agent secukinumab (SEC) has been proven effective and is widely used in the treatment of spondyloarthritis (SpA) patients alternatively to tumor necrosis factor…
Abstract Number: 1257 • ACR Convergence 2023
The Psychological Experience of Work for People with Inflammatory Arthritis (IA)
Joan Westreich¹, Adena Batterman¹, Anna Balakrishnan¹, Roberta Horton¹, Minerva Nong¹, Vivian Bykerk² and Theodore Fields¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: A large body of research reports that people with inflammatory arthritis (IA) are at increased risk for work disability, which profoundly affects all aspects…
Abstract Number: 1409 • ACR Convergence 2023
Analysis of Soluble Biomarkers in Axial Spondyloarthritis
Caroline Bauchiero¹, Stephanie Sinnappan² and Joerg Ermann³, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Distinguishing patients with axial spondyloarthritis (axSpA) from patients with other causes of chronic back pain remains a challenge. The lack of reliable biomarkers contributes…
Abstract Number: 1849 • ACR Convergence 2023
Impact of the First Three Waves of the Covid-19 Pandemic on Everyday Restrictions and Clinical Care of Patients with Spondyloarthritis Across Europe – Results from the EuroSpA Collaboration
Brigitte Michelsen¹, Bente Glintborg², Kim Lauper³, Bjorn Gudbjornsson⁴, Lykke Ørnbjerg⁵, Gerdur Maria Gröndal⁶, Karin Laas⁷, Sigrid Vorobjov⁸, Dan Nordstrom⁹, Heikki Relas⁹, Adrian Ciurea¹⁰, Burkhard Moeller¹¹, Isabel Castrejon¹², Lucia Otero-Valera¹³, Ziga Rotar¹⁴, Katja Perdan Pirkmajer¹⁵, Anne Gitte Loft¹⁶, Jakub Zavada¹⁷, Karel Pavelka¹⁸, Eirik Kristianslund¹⁹, Tore Kvien²⁰, Marleen van de Sande²¹, Pasoon Hellamand²², Florenzo Iannone²³, Roberto F. Caporali²⁴, Ana Maria Rodrigues²⁵, Maria Jose Santos²⁶, Catalin Codreanu²⁷, Corina Mogosan²⁸, Merete Hetland⁵ and Mikkel Østergaard²⁹, ¹Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ²Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ³Geneva University Hospitals, Genève, Switzerland, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶Landspitali University Hospital; University of Iceland, Reykjavik, Iceland, ⁷Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ⁸National Institute for Health Development, Tallinn, Estonia, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰University Hospital Zurich, Zürich, Switzerland, ¹¹Inselspital - University Hospital Bern, Bern, Switzerland, ¹²Hospital Universitario Gregorio Marañón, Madrid, Spain, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁵University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ¹⁶Aarhus University, Horsens, Denmark, ¹⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ¹⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ¹⁹Diakonhjemmet Hospital, Oslo, Norway, ²⁰Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ²⁵Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²⁶Hospital Garcia de Orta, Almada, Lisboa, Portugal, ²⁷Center for Rheumatic Diseases, Bucharest, Romania, ²⁸University of Medicine and Pharmacy, Bucharest, Romania, ²⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The Covid-19 pandemic constituted major challenges for health-care services worldwide. We aimed to compare Covid-19 restrictions across Europe during the first three waves of…
Abstract Number: 2200 • ACR Convergence 2023
Sensitivity to Change of Structural Outcomes in Early Axial Spondyloarthritis After 10 Years of Follow Up. Data from DESIR Cohort
Clementina López Medina¹, Anna Molto², Alexandre Sepriano³, Sofia Ramiro⁴ and Maxime Dougados⁵, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France
Background/Purpose: The change over time of the structural damage of axial spondyloarthritis (axSpA) is important to consider since it may reflect the severity of the…
Abstract Number: 2219 • ACR Convergence 2023
Comparing the Construct Validity Among Measures of Pain and Stiffness in Patients with Axial Spondyloarthritis
Dafne Capelusnik¹, Elena Nikiphorou², Annelies Boonen³, Désirée van der Heijde⁴, Robert BM Landewé⁵, Astrid van Tubergen⁶ and Sofia Ramiro⁴, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²King's College London, London, United Kingdom, ³Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Herleen, Netherlands, ⁶Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands
Background/Purpose: In the context of the recent update of the ASAS core outcomes set (COS), the preferred comparative validity of the measurement instruments to assess…
Abstract Number: PP09 • ACR Convergence 2023
Practicing Mindfulness to Improve Quality of Life
Vanessa Patino-Lydia, Global Healthy Living Foundation, Hallandale, FL
Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…
Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Tal Gazitt¹, Noa Hayat², Amir Haddad², Joy Feld³, Nili Stein², Idit Lavi², Ilan Feldhamer⁴, Arnon Dov Cohen⁵, Walid Saliba² and Devy Zisman², ¹Carmel Hospital, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…
Abstract Number: 0516 • ACR Convergence 2023
Drivers of Treatment Intensification in Patients with Axial Spondyloarthritis and High Disease Activity: Results from a Clinical Practice Registry
Casper Webers¹, Rabab Nezam El-Din¹, Marin Been¹, Harald Vonkeman² and Astrid van Tubergen¹, ¹Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, Netherlands, ²Department of Rheumatology, Medisch Spectrum Twente and University of Twente, Enschede, Netherlands
Background/Purpose: In the management of axial spondyloarthritis (axSpA), treatment intensification (TI) is recommended in patients with high disease activity (HDA). However, in practice, in most…

« Previous Page
1
…
8
9
10
11
12
…
41
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].